Ohio University

skip to main content
Konneker Research Laboratories Building

Research & Commercialization

Though EBI comprises less than one percent of the Ohio University faculty, commercialization of technologies from EBI generated approximately $100 million as of the end of 2016, more than 95 percent of the university’s royalty income.

Research at the institute continues a tradition of basic research combined with a disciplined, practical focus on commercialization in order to apply discoveries to the benefit of human health. Our research in molecular and cellular biology, genetics, proteomics, and hormonal regulation addresses unmet therapeutic needs in the areas of:

  • Growth disorders
  • Diabetes and obesity
  • Autoimmune diseases
  • Inflammation
  • Neurodegeneration
  • Aging
  • Infectious diseases    
  • Cancer

These research themes are being pursued for the development of biomedical diagnostics and therapeutics both individually at EBI and in collaboration with other academic and corporate partners. Over the past three decades, this interdisciplinary and entrepreneurial approach has produced:

  • 30 U.S. patents
  • 1 U.S. patent applications pending
  • 25 active invention disclosures

This science continues our best tradition and mission of enhancing not only human health globally but also the economic health of the southeastern Ohio region.

Funding Sources

The Edison Biotechnology Institute is supported by the Ohio Department of Development, the Goll-Ohio Eminent Scholar Endowment, Ohio University, federal agencies, foundations, corporate sponsored research agreements, royalty revenues, and gifts.